A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing

S. Paiella, D. Azzolina, D. Gregori, G. Malleo, T. Golan, D. M. Simeone, M. B. Davis, P. G. Vacca, A. Crovetto, C. Bassi, R. Salvia, A. V. Biankin*, R. Casolino*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background: Germline BRCA1 and BRCA2 mutations (gBRCAm) can inform pancreatic cancer (PC) risk and treatment but most of the available information is derived from white patients. The ethnic and geographic variability of gBRCAm prevalence and of germline BRCA (gBRCA) testing uptake in PC globally is largely unknown. Materials and methods: We carried out a systematic review and prevalence meta-analysis of gBRCA testing and gBRCAm prevalence in PC patients stratified by ethnicity. The main outcome was the distribution of gBRCA testing uptake across diverse populations worldwide. Secondary outcomes included: geographic distribution of gBRCA testing uptake, temporal analysis of gBRCA testing uptake in ethnic groups, and pooled proportion of gBRCAm stratified by ethnicity. The study is listed under PROSPERO registration number #CRD42022311769. Results: A total of 51 studies with 16 621 patients were included. Twelve of the studies (23.5%) enrolled white patients only, 10 Asians only (19.6%), and 29 (56.9%) included mixed populations. The pooled prevalence of white, Asian, African American, and Hispanic patients tested per study was 88.7%, 34.8%, 3.6%, and 5.2%, respectively. The majority of included studies were from high-income countries (HICs) (64; 91.2%). Temporal analysis showed a significant increase only in white and Asians patients tested from 2000 to present (P < 0.001). The pooled prevalence of gBRCAm was: 3.3% in white, 1.7% in Asian, and negligible (<0.3%) in African American and Hispanic patients. Conclusions: Data on gBRCA testing and gBRCAm in PC derive mostly from white patients and from HICs. This limits the interpretation of gBRCAm for treating PC across diverse populations and implies substantial global and racial disparities in access to BRCA testing in PC.

Original languageEnglish
Article number100881
JournalESMO Open
Volume8
Issue number2
DOIs
StatePublished - Apr 2023

Funding

FundersFunder number
Fondazione Italiana Malattie Pancreas
Pancreatic Cancer UK Future Research Leaders FundFLF2015_04_Glasgow
Scottish Genomes PartnershipSEHHD-CSO 1175759/2158447
Wellcome Trust103721/Z/14/Z
Wellcome Trust
Cancer Research UKC596/A18076, C29717/A17263, C29717/A18484, A23526, C596/A20921
Cancer Research UK
Ministero della SaluteCUP_J38D19000690001
Ministero della Salute
Howat Foundation

    Keywords

    • BRCA
    • disparities
    • germline testing
    • pancreatic cancer

    Fingerprint

    Dive into the research topics of 'A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing'. Together they form a unique fingerprint.

    Cite this